Myomo, Inc. (NYSEAMERICAN:MYO - Free Report) - Analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for shares of Myomo in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.18) per share for the year, down from their previous estimate of ($0.16). HC Wainwright has a "Buy" rating and a $7.50 price target on the stock. The consensus estimate for Myomo's current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Myomo's Q4 2024 earnings at ($0.02) EPS, Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at $0.03 EPS, FY2025 earnings at ($0.12) EPS, FY2026 earnings at $0.05 EPS and FY2027 earnings at $0.21 EPS.
Myomo (NYSEAMERICAN:MYO - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.01. Myomo had a negative return on equity of 86.30% and a negative net margin of 33.22%. The firm had revenue of $9.21 million during the quarter, compared to the consensus estimate of $7.95 million.
MYO has been the topic of several other reports. Ascendiant Capital Markets boosted their price objective on shares of Myomo from $8.50 to $9.00 and gave the company a "buy" rating in a report on Tuesday. Craig Hallum started coverage on shares of Myomo in a report on Wednesday, July 31st. They issued a "buy" rating and a $7.00 price objective on the stock.
Check Out Our Latest Report on MYO
Myomo Stock Down 3.9 %
Shares of NYSEAMERICAN MYO traded down $0.19 during trading on Friday, hitting $4.66. 192,970 shares of the company were exchanged, compared to its average volume of 327,811. Myomo has a 12-month low of $2.51 and a 12-month high of $5.64. The firm has a market cap of $140.97 million, a PE ratio of -20.17 and a beta of 1.56.
Hedge Funds Weigh In On Myomo
A number of institutional investors and hedge funds have recently made changes to their positions in MYO. Accel Wealth Management lifted its stake in Myomo by 6.0% during the second quarter. Accel Wealth Management now owns 43,882 shares of the company's stock worth $141,000 after purchasing an additional 2,500 shares during the last quarter. Barclays PLC purchased a new stake in Myomo during the third quarter worth approximately $36,000. Jane Street Group LLC purchased a new stake in Myomo during the third quarter worth approximately $65,000. Vontobel Holding Ltd. purchased a new stake in Myomo during the third quarter worth approximately $90,000. Finally, Bailard Inc. purchased a new stake in Myomo during the second quarter worth approximately $109,000. 44.99% of the stock is owned by institutional investors and hedge funds.
Myomo Company Profile
(
Get Free Report)
Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.
Featured Stories
Before you consider Myomo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myomo wasn't on the list.
While Myomo currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
